GALT
GALT
NASDAQ · Biotechnology

Galectin Therapeutics Inc

Penny Stocks Biotech Stocks Healthcare Stocks
$2.35
+0.12 (+5.38%)
As of May 16, 2:07 AM ET ·
Analyst Consensus
Strong Buy
7
Analysts
Moderate
Coverage
Buy 6 86%
Hold 1 14%
Sell 0 0%
Price Target
Analyst Price Target +451.5% upside
Low Target $9.51
Average Target $12.96
High Target $17.52
Current Price $2.35
Current
$2.35
Target
$12.96
$9.51 $12.96 avg $17.52
Scenario Analysis
Bear Case
$9.51
304.7%
Low target
Base Case
$12.96
+451.5%
Avg target
Bull Case
$17.52
+645.5%
High target
Risk/Reward
2.1x
Favorable
Price in Context
52-Week High
$7.13
-67.0% from high
52-Week Low
$1.21
+94.2% from low
Target vs 52W High
$12.96
+81.8% vs high
Next Earnings Report
May 18, 2026
Today
EPS Est: $-0.06
Earnings in today. Analyst targets may shift significantly after the report.
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
 Strong Buy 40 75% $257.58 +22.4%
AMGN
Amgen Inc
 Hold 44 48% $190.87 -41.5%
GILD
Gilead Sciences Inc
 Strong Buy 39 79% $362.68 +179.9%
VRTX
Vertex Pharmaceuticals Inc
 Strong Buy 39 79% $438.34 +0.3%
REGN
Regeneron Pharmaceuticals
 Strong Buy 38 79% $76.80 -89.0%
ALNY
Alnylam Pharmaceuticals Inc
 Strong Buy 36 75% $102.31 -64.3%
RVMD
Revolution Medicines Inc
 Strong Buy 27 96% $114.11 -21.7%
BIIB
Biogen Inc
 Buy 43 56% $91.45 -52.6%